From Patent to Patient: Analysing access to innovative cancer drugs – Institute of Cancer Research

Report that looks at how to best harness advances in science to bring innovative drugs to patients. It is designed to help us reshape the landscape for drug discovery and development – and create tomorrow’s cancer treatments.

International Development Research Funders Statement on Safeguarding – UKCDR

Research organisations: commitments to tackle sexual exploitation and abuse and sexual harassment in the international aid sector.

Innovation in AMR: patent trends for novel diagnostics – Nesta

Research into patents and connected patent families using keywords relevant to point-of-care (POC) diagnostic tests for addressing antimicrobial resistance. This research analysed what patents are being filed and therefore what technology is being developed. The report assesses the implications on

Seven principles for public engagement in research and innovation policymaking: A guide from Nesta’s Inclusive Innovation team – Nesta

Why should researchers, innovators and those whose jobs it is to regulate technology engage with people who aren’t like them on topics like research and innovation? To give those in power a broader range of potential futures to aspire to

Ensuring access to medicines: How to stimulate innovation to meet patients’ needs?: (Policy Brief 29) – European Observatory on Health Systems and Policies

Brief that aims to inform discussions about stimulating more meaningful productivity in terms of pharmaceutical R&D. More specifically, it explores how R&D efforts can be steered to areas of unmet clinical needs and how efficiency in the R&D process can

Research integrity: clinical trials transparency: Tenth Report of Session 2017–19 Report, together with formal minutes relating to the report – House of Commons Science and Technology Committee

Selective non-publication of the results of research distorts the published evidence base and is a threat to research integrity. In the case of clinical trials, non-publication of results means that information on the efficacy of new drugs or other medical

National Directive on Commercial Contract Research Studies – NHS England

The National Directive on Commercial Contract Research Studies sets out the requirements providers will need to adhere to for commercial contract research.

World Alzheimer Report 2018: The State Of The Art Of Dementia Research: New Frontiers – Alzheimer’s Disease International

Alzheimer’s Disease International report that looks at a broad cross section of research areas including basic science; diagnosis; drug discovery; risk reduction and epidemiology. With the continued absence of a disease modifying treatment, the report also features progress, innovation and developments

NHS England’s Research Needs Assessment 2018 – NHS England

This publication summarises information and areas for research identified by NHS England’s six national priority programmes (Urgent & Emergency Care (UEC), Mental Health, Primary Care, Cancer, Diabetes and Specialised Commissioning), and the medical and nursing directorates.

Seven principles for public engagement in science and innovation policymaking: A guide from Nesta’s Inclusive Innovation team – Nesta

Why should researchers, innovators and those whose jobs it is to regulate technology engage with people who aren’t like them on topics like research and innovation? To give those in power a broader range of potential futures to aspire to

2010 Year of Health and Wellbeing Evaluation Report – Liverpool Primary Care Trust

Report that evaluates a joint working approach to public health.  Key outcomes of this approach were that it: publicly articulates the solidarity between key agencies to working collaboratively with all partners and communities. provides a strong framework for partnership working across

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C: (Research Paper 18/06) – Office of Health Economics

Report analysing the functioning of a specific market for innovative treatments, Direct Acting Antivirals (DAAs) for hepatitis C virus (HCV), in six European countries. It explores the potential for in-class competition for DAAs to offset innovators’ market power and maximise the social welfare

The Biomedical Bubble: Why UK research and innovation needs a greater diversity of priorities, politics, places and people – Nesta

This report sets out why and how the UK needs to escape the biomedical bubble if it is to realise the economic, social and health potential of new investment in research and development.  It identifies that much of the wider innovation

Evidence synthesis for policy: A statement of principles – Royal Society and Academy of Medical Sciences

Evidence synthesis supports well-founded policymaking and public debate. The common question ‘What is the evidence for that?’ could be usefully rephrased as ‘Has sufficient synthesis of the evidence been done in relation to that?’. While typically asked in the former way, it is really the

A recipe for action: using wider evidence for a healthier UK: A collection of essays exploring why we need trans-disciplinary approaches to improve the public’s health – The Health Foundation

It is increasingly recognised that addressing the current challenges facing people’s long-term health outcomes in the UK isn’t simply a problem of translation and access to existing evidence. It is a more fundamental problem: the evidence relevant to population-level action

NHS Innovation and Technology Payment 2018/19 Call for Applications – NHS England

Innovation Technology Payment (ITP) – Call for Applications and Guidance document. The aim of the NHS Innovation and Technology Payment (ITP) is to help deliver on the commitment detailed within the Five Year Forward View -creating the conditions and cultural change necessary

Citizen science: crowdsourcing for research – The Healthcare Improvement Studies Institute

Healthcare Improvement Studies Institute, Rand Europe and Health Foundation report that looks at the use of crowdsourcing in research and the power of citizen science to generate ideas, solve problems, and work together to deliver on scientific goals. It considers

The Human Factor: Driving Digital Solutions for 21st Century Health and Care – National Centre for Universities and Business

Report that identifies the digital skills gap which is hindering adoption of digital health and care innovation at scale; the need to share data for sustainable service delivery, patient and user outcome improvements, high quality research and commercial success; the

Strength and Opportunity 2017: The landscape of the medical technology and biopharmaceutical sectors in the UK – Department of Health and Social Care, Department for Business, Energy & Industrial Strategy, and Office for Life Sciences

This annual report analyses the updated 2017 dataset from the bioscience and health technology database. The data relates to companies that are active in the UK in the health life sciences sectors: medical technology bio-pharmaceuticals This report shows that the

Life Science Competitiveness Indicators – Office for Life Sciences

Charts providing information on the UK life science sector, and how it compares to other countries. Areas covered include: UK industry research and development regulatory environment clinical research